We investigated the role of radiation-induced mitogen activated protein kinase (MAPK) pathway activity in the regulation of proliferation, cell survival and vascular endothelial growth factor (VEGF) production in primary astrocytes and in T9 and RT2 glioblastoma cells derived from Fisher 344 rats. In these cells, ionizing radiation (2 Gy) caused activation of the MAPK pathway which was blocked by speci®c inhibitor drugs. Blunting of radiationinduced MAPK activity weakly enhanced radiationinduced apoptosis 24 h after exposure in RT2 cells. Furthermore, blunting of MAPK activation weakly enhanced the ability of radiation to reduce RT2 cell growth in clonogenic growth assays. These ®ndings argue that inhibition of MAPK signaling reduces proliferation and enhances cell killing by ionizing radiation in transformed astrocytes. Proliferation and survival of cancer cells has been linked in vivo to enhanced expression of angiogenic growth factors. Recently we demonstrated that the gene product of a novel rodent radiationresponsive gene, progression elevated gene 3 (PEG-3), could enhance vascular endothelial growth factor (VEGF) promoter activity in rodent ®broblasts, leading to increased VEGF protein levels and tumorigenic behavior in vivo. Thus PEG-3 and VEGF expression could be expected to directly correlate with the oncogenic potential of transformed cells. RT2 cells expressed more PEG-3 and VEGF protein than T9 cells, and were more tumorigenic in vivo than T9 cells. Radiation activated the PEG-3 promoter via MAPK signaling and ectopic over-expression of PEG-3 enhanced both basal MAPK activity and basal VEGF promoter activity. Basal MAPK activity partially correlated with basal VEGF promoter activity and VEGF protein levels in primary astrocytes, T9 and RT2 cells.
Introduction
Ionizing radiation is used as a primary treatment for many types of cancer, including those of the breast, prostate and brain. However, the mechanisms by which radiation can either increase cell death or alter the proliferative rate of surviving cells are not understood. Recently, radiation has been shown to activate multiple signaling pathways within cells which can alter cell survival or proliferation depending upon the radiation dose, the cell type, and the culture conditions (Carter et al., 1998; Xia et al., 1995; Chmura et al., 1997; Santana et al., 1996) . Several groups have shown that the epidermal growth factor receptor (EGFR, also called ErbB1) is activated in response to irradiation of squamous and mammary carcinoma cells (Carter et al., 1998; Schmidt-Ullrich et al., 1997; Kavanagh et al., 1998; Balaban et al., 1996; Dent et al., 1999) . Radiation exposure, via activation of the EGFR, can activate the mitogen activated protein kinase (MAPK) pathway to a level similar to that observed by physiologic, growth stimulatory, EGF concentrations (*0.1 nM) (Schmidt-Ullrich et al., 1997; Kavanagh et al., 1998; Dent et al., 1999; Suy et al., 1997; .
The proliferation of many carcinoma cells in vitro and in vivo is in part regulated by the synthesis and autocrine actions of ligands such as transforming growth factor a (TGFa) Levenson et al., 1998) and vascular endothelial growth factor (VEGF) (Slevin et al., 2000; Hossain et al., 2000; Mazure et al., 1997; Zundel et al., 2000) . Irradiation of tumor cells can both increase expression of TGFa and activate the EGFR, and this has been proposed to increase the proliferative rate of surviving cells (Levenson et al., 1998; Baselga et al., 1996; SchmidtUllrich et al., 1992; Putz et al., 1999) . Increased proliferative rates and poor prognosis of carcinomas in vivo are also correlated with increased expression of the EGFR (Baselga et al., 1996; Schmidt-Ullrich et al., 1992; Putz et al., 1999) . MAPK signaling has also been linked to increased expression of growth factors such as VEGF (Pages et al., 2000; Rak et al., 2000; Li et al., 2000) . Growth factors such as VEGF and TGFa, in addition to a growth promoting role in vitro, may also play an important role in the development of tumors in vivo due to their abilities in the promotion of angiogenesis (Slevin et al., 2000; Hossain et al., 2000; Mazure et al., 1997; Zundel et al., 2000; Pages et al., 2000; Rak et al., 2000; Li et al., 2000; Minet et al., 1999) . Collectively, these ®ndings argue that radiation may have a self-limiting eect on its toxicity via increased activity of EGFR and downstream signaling modules such as the MAPK pathway. In addition, since radiation can activate the MAPK pathway, it is possible that radiation could stimulate angiogenesis and tumor cell development via this mechanism.
Recently, increased signaling by the MAPK pathway has been shown to be cytoprotective versus ionizing radiation and various cytotoxic drugs in diverse cancer cell lines, although the precise mechanism(s) by which this occurred were unclear (Carter et al., 1998; Reardon et al., 1999; Gokhale et al., 1999; Goldkorn et al., 1997; Park et al., 1999; Hagan et al., 2000; Cartee et al., 2000; Abbott and Holt, 1999) . Of note, others have not observed MAPK signaling to be protective (e.g. Gupta et al., 2000) , which in part may be explained by both cell line dierences, serum starvation, and the fact that the ability of MAPK inhibition to sensitize cells in colony formation assays required a prolonged 448 h blunting of MAPK function (Hagan et al., 2000) . That cytotoxic stresses can activate MAPK also supports the concept that certain stresses may have a self limiting eect upon their toxicity due to activation of the MAPK pathway.
Tumors of the brain, in particular glioblastoma multiforme (GBM), are often rapidly growing vascularized tumors. The primary therapeutic strategy in GBM is surgery followed by radiotherapy, however despite these interventions, such tumors frequently have a high morbidity, with 50% survival rates of less than 30 months (Kraus et al., 2000; Huhn et al., 1999) . Several animal model systems have been used to examine GBM, including the Fisher 344 rat and the syngeneic cell lines T9 and RT2 (Barth, 1998) . T9 and RT2 cells have been shown to have dierent tumor growth rates in vivo, with RT2 cells growing faster and killing animals more rapidly.
These studies were designed to determine whether MAPK signaling can protect transformed astrocytes (T9 and RT2 cells) from the toxic eects of ionizing radiation. In addition, since MAPK signaling has been proposed to modify the function of the VEGF promoter as well as VEGF expression in other systems, we investigated whether radiation-induced MAPK signaling increased VEGF levels in astrocytes.
Results
Radiation induces activation of the MAPK pathway in primary astrocytes, T9 and RT2 glioblastoma cell lines
The ability of radiation (2 Gy) to modulate MAPK activity was investigated in primary astrocytes, T9 and RT2 glioblastoma cells shortly following radiation exposure (0 ± 180 min) (Figure 1 ). Basal MAPK speci®c activity was lowest in primary astrocytes (de®ned as 1.00) which was increased by an order of magnitude in T9 glioblastoma cells (Figure 1a ). RT2 cells exhibited a 40-fold increase in basal MAPK activity compared to primary astrocytes.
In primary astrocytes and T9 cells, a single exposure to radiation (2 Gy) caused a weak, about twofold, activation of the MAPK pathway (Figure 1b,c) . A greater, approximately fourfold, activation of MAPK in response to radiation was observed in RT2 cells (Figure 1d ). Chemical inhibition of the EGFR function, by use of the ErbB1 speci®c tyrphostin AG1478, reduced, but did not abolish, radiationinduced MAPK activation in RT2 cells. This is in contrast to the complete dependence of radiationinduced MAPK signaling on EGFR function in other cancer cells previously studied by this laboratory Park et al., 1999; Hagan et al., 2000) . Incubation of cells with a speci®c inhibitor of MEK1/2, 10 mM PD98059, reduced basal MAPK activity, and abolished the ability of radiation to activate MAPK (Figure 1a,d ). Similar data were obtained using the chemically dissimilar MEK1/2 inhibitors U0126 and SL327 (data not shown). These data demonstrate that radiation increases MAPK activity in primary and transformed astrocytes.
Since we observed a large radiation-induced increase in MAPK activity in RT2 cells within 180 min, we next investigated whether MAPK activity was modi®ed over a more prolonged period of time. Basal MAPK speci®c activity did not alter in control samples over a 24 h time course, and radiation caused a modest 50% increase in MAPK activity 6 ± 12 h after exposure, which was still evident at 24 h (Figure 2a ). Both activation of MAPK by radiation and basal MAPK activity were blunted by PD98059 throughout the 24 h time period. Since basal MAPK activity was increased by *50% after 24 h, we hypothesized that prior irradiation would enhance MAPK activation by a subsequent radiation exposure. In agreement with this hypothesis, a prior radiation exposure of 2 Gy Primary astrocytes, T9 or RT2 cells were treated with either vehicle (VEH, DMSO), EGFR inhibitor tyrphostin AG1478 (100 nM) or MEK1/2 inhibitors (U0126, 2 mM; SL327; PD98059, 10 mM) 30 min prior to irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and MAPK activity determined over 0 ± 240 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to immunoprecipitate MAPK followed by immune-complex kinase assays as in Materials and methods. Error bars are shown when greater than the datum symbol. (a) Basal MAPK speci®c activity in primary astrocytes, T9 and RT2 cells. MAPK activity data are shown as -fold increases in 32 P-incorporation into MBP substrate, and are normalized to the speci®c activity in primary astrocytes at time=0 from the means+s.e.m. of three independent experiments. *P50.05 less than vehicle treated cell. (b) MAPK activation in primary astrocytes induced by radiation. MAPK activity data are shown as -fold increases in 32 P-incorporation into MBP substrate, and are normalized to the speci®c activity in primary astrocytes at time=0 from the means+s.e.m. of three independent experiments. (c) MAPK activation in T9 cells induced by radiation. MAPK activity data are shown as -fold increases in 32 P-incorporation into MBP substrate, and are normalized to the speci®c activity in T9 cells at time=0 from the means+s.e.m. of three independent experiments. (d) MAPK activation in RT2 cells induced by radiation. MAPK activity data are shown as -fold increases in 32 P-incorporation into MBP substrate, and are normalized to the speci®c activity in RT2 cells at time=0 from the means+s.e.m. of three independent experiments enhanced MAPK activation by an additional 2 Gy exposure 24 h later about twofold (Figure 2b ). The data in Figures 1 and 2 argue that in transformed astrocytes, radiation can stimulate MAPK activity over prolonged periods of time and that multiple radiation exposures can enhance MAPK basal activity and potentiate further MAPK activation(s).
Radiation-induced MAPK signaling regulates the PEG-3-and VEGF-promoters, and protein levels, in primary astrocytes and glioma cells Proliferation and survival of cancer cells has been linked to both in vitro and in vivo to increased MAPK activity and in vivo to enhanced expression of autocrine and angiogenic growth factors. Recently, one of our laboratories demonstrated that the gene product of a novel radiation-responsive gene, termed progression elevated gene 3 (PEG-3), could enhance the activity of the VEGF promoter in ®broblasts, leading to increased VEGF protein levels (Su et al., 1997 (Su et al., , 1999 (Su et al., , 2000 . Enhanced PEG-3 expression was also shown to promote tumorigenesis in vivo, and antisense-inhibition of PEG-3 expression in Ras-transformed cells abolished their in vivo tumorigenic potential. Additional studies have more recently shown that the PEG-3 promoter is under the control of both the Ets-family transcription factor PEA3 and the AP-1 transcription factor complex, which are potential downstream targets of MAPK and JNK signaling (Su et al., 2000; Conrad et al., 1999) . Thus we examined whether any interaction occurred between radiation, MAPK signaling, and the expression/promoter functions of PEG-3 and VEGF in glioblastoma cells.
A single 2 Gy radiation exposure caused weak, moderate and strong enhancements of PEG-3 promoter function in primary astrocytes, T9 cells and RT2 cells, respectively (Figure 3a ,b,c). Radiation-induced PEG-3 promoter activity was blocked by inhibition of MAPK signaling in all three cell types. However, while basal MAPK activity increased *40-fold comparing primary astrocytes and RT2 cells, PEG-3 promoter activity was only increased about twofold comparing these cells. In contrast to promoter activity levels, protein levels of PEG-3 were highly divergent comparing primary astrocytes, T9 and RT2 cells (Figure 3d , upper panel). PEG-3 protein expression was undetectable in primary astrocytes. This data suggests that some form of post-transcriptional stabilization of PEG-3 takes place in RT2 cells. In agreement with a role for radiation-induced MAPK signaling playing a role in the control of PEG-3 promoter function, inhibition of MAPK activation blocked the radiation-induced enhancement of PEG-3 protein levels in RT2 cells ( Figure  3d , lower panel).
In agreement with previous ®ndings in ®broblasts (Su et al., 1997 (Su et al., , 1999 (Su et al., , 2000 , ectopic over-expression of PEG-3 protein in primary astrocytes increased basal MAPK activity and VEGF promoter function, both by approximately eightfold (Figure 4 ). In contrast, antisense ablation of PEG-3 expression in RT2 cells reduced both basal MAPK activity and VEGF promoter function (Figure 4b ). No expression of the hypoxia-inducible factor, HIF1a, was observed in 30 min prior to irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and MAPK activity determined over 0 ± 24 h as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to immunoprecipitate MAPK followed by immune-complex kinase assays as in Materials and methods. MAPK activity data are shown as -fold increases in 32 P-incorporation into MBP substrate, and are normalized to speci®c activity at time=0 from the means+s.e.m. of three independent experiments. Error bars are shown when greater than the datum symbol. (b) Prior irradiation of RT2 cells enhances MAPK activation by a subsequent exposure. RT2 cells were irradiated (2 Gy) and 24 h after the initial exposure, were treated with MEK1/2 inhibitor (PD98059, 10 mM) 30 min prior to the second irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and MAPK activity determined over 0 ± 120 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to immunoprecipitate MAPK followed by immune-complex kinase assays as in Materials and methods. MAPK activity data are shown as -fold increases in 32 P-incorporation into MBP substrate, and are normalized to speci®c activity at time=0 from the means+s.e.m. of three independent experiments either primary astrocytes or RT2 cells, suggesting that these phenomena are independent of HIF1a transcriptional control of the VEGF promoter in these astrocytic cells (data not shown). Collectively, the data in Figures 3 and 4 suggest that MAPK signaling regulates PEG-3 protein levels at a transcriptional a b c d Figure 3 Radiation activates the PEG-3 promoter via MAPK signaling. (a) Twenty-four hours prior irradiation, primary astrocytes were transfected with a luciferase reporter construct coupled to the PEG-3 promoter. After 24 h, cells were treated with either vehicle (VEH, DMSO) or MEK1/2 inhibitor (PD98059, 10 mM) 30 min prior to irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and PEG-3 promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. PEG-3-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 and the transfection eciency of the reporter plasmid between cells. (n=3+s.e.m.). Error bars are shown when greater than the datum symbol. (b) Twenty-four hours prior irradiation, T9 cells were transfected with a luciferase reporter construct coupled to the PEG-3 promoter. After 24 h, cells were treated with MEK1/2 inhibitor (PD98059, 10 mM) 30 min prior to the second irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and PEG-3 promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. PEG-3-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 and the transfection eciency of the reporter plasmid between cells. (n=3+s.e.m.). (c) Twenty-four hours prior irradiation, RT2 cells were transfected with a luciferase reporter construct coupled to the PEG-3 promoter. After 24 h, cells were treated with MEK1/2 inhibitor (PD98059, 10 mM) 30 min prior to the second irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and PEG-3 promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. PEG-3-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 and the transfection eciency of the reporter plasmid between cells. (n=3+s.e.m.). (d) Upper section, expression of PEG-3 protein in primary astrocytes, T9 and RT2 cells; Lower section, PEG-3 protein expression in RT2 cell lysates taken from the 180 min time point in (c). Portions of lysates (*100 mg) from each plate were used to determine PEG-3 protein levels by SDS ± PAGE and immunoblotting as in Materials and methods. A representative experiment is shown (n=3) level, and that PEG-3 expression can play a role, potentially via enhanced MAPK signaling, in controlling basal VEGF promoter function in astrocytes. We next examined whether radiation-induced MAPK signaling controlled the function of the VEGF promoter and VEGF protein levels in astrocytes and glioma cells. A single 2 Gy radiation exposure caused moderate, strong and very strong enhancements of VEGF promoter function in primary astrocytes, T9 cells and RT2 cells, respectively (Figure 5a,b,c) . Radiation-induced VEGF promoter activity was blocked by inhibition of MAPK. Of note, while transfection with dominant negative MEK1 blocked radiation-induced VEGF promoter activation 24 h following transfection, it did not block promoter activation 48 ± 60 h after transfection (data not shown). This ®nding suggests that RT2 cells can circumvent the ability of dominant negative MEK1 to inhibit MAPK pathway function during prolonged cell culture.
In contrast to our ®ndings with the PEG-3 promoter where a 40-fold increase in basal MAPK activity correlated with a fourfold increase in PEG-3 promoter activity, basal MAPK activity in each cell type ( Over-expression of PEG-3 increases MAPK activity which is responsible for enhanced VEGF promoter function. Primary astrocytes and RT2 cells were infected with a control recombinant adenovirus or either recombinant adenoviruses to express PEG-3 or PEG-3 antisense mRNA, respectively, at a multiplicity of infection of 30. Forty-eight hours after infection, cells were treated with either vehicle control (VEH, DMSO) or 10 mM PD98059. After an additional 12 h, cells were harvested and MAPK activity, expression of PEG-3, and expression of HIF1a determined by immunoblotting. In parallel studies, cells were also transfected with the VEGF promoter and VEGF promoter function determined using luciferase assays as in Materials and methods. Error bars are shown when greater than the datum symbol. (a) Over expression of PEG-3 in primary astrocytes increases basal MAPK activity and VEGF promoter function, which is inhibited by PD98059. Data are +s.e.m. (24 h), primary astrocytes were transfected with a luciferase reporter construct coupled to the VEGF promoter. After 24 h, cells were treated with either vehicle control (VEH, DMSO) or MEK1/2 inhibitor (PD98059, 10 mM) 30 min prior to irradiation, as described function ( Figure 5 ), which was also re¯ected in the relative basal expression levels of VEGF protein (Figure 5d, upper panel) . In addition, we observed a partial correlation of a dose dependent reduction of basal VEGF promoter activity following MAPK inhibition (Figure 5e ), and complete inhibition of MAPK activity with *100 mM PD98059 resulted in a *40% reduction of VEGF promoter activity within 2 ± 3 h. A *35% inhibition of MAPK activity with 10 mM PD98059, lowered basal VEGF promoter function by *10 ± 20% and blocked the radiationinduced enhancement of VEGF protein levels in these cells (Figure 5d , lower panel). Radiation very weakly increased VEGF protein expression 2.4+0.8-fold in RT2 cells within 4 h. Collectively, these data demonstrate that radiation can increase VEGF promoter function in glioblastoma cells via the MAPK pathway.
Inhibition of AP-1 function by dominant negative c-Jun (TAM67) blunts radiation-induced VEGF promoter activation Since RT2 cells did not express measurable amounts of HIF1a, but radiation could still activate the VEGF promoter, it was apparent that radiation must be recruiting another additional transcriptional mechanism in these cells. Recently, Hossain et al. (2000) have argued that the AP-1 transcription factor complex can play an HIF1a-independent role in the activation of the VEGF promoter. Thus we next investigated whether concerted signaling via both the MAPK and c-Jun NH 2 -terminal kinase (JNK) pathways could modulate VEGF promoter function in RT2 cells (Figure 6 ).
Radiation activated the JNK pathway in RT2 cells with similar kinetics to that observed for MAPK (Figure 6a ; compare to Figure 1d ). In cells transfected with the VEGF promoter and dominant negative c-Jun (TAM67) , the ability of radiation to stimulate VEGF promoter activity was signi®cantly reduced (Figure 6b ). Radiation also enhanced AP-1 DNA binding in EMSA (data not shown). These data argue that coordinated signaling from MAPK and JNK pathways to the AP-1 transcription factor complex can play a role in the radiation-induced promoter function and expression of VEGF.
Inhibition of the MAPK activity blunts growth of RT2 cells MAPK signaling has been proposed to play an important role in the growth of many cell types. To assess the role of MAPK signaling in the control of RT2 cell growth, we incubated cells in the presence of increasing concentrations of PD98059 and determined DNA synthesis over the following 24 h by 3 Hthymidine incorporation into DNA. When cells were incubated in media containing 10 mM PD98059, a drug concentration which inhibited basal MAPK activity by *35% and abolished radiation-stimulated MAPK activity, DNA synthesis was blunted by *30% ( Figure  7 ). This data suggests that a portion of the growth factor-induced mitogenic signals enhancing DNA synthesis in RT2 cells are mediated by the MAPK pathway.
Inhibition of MAPK enhances radiation-induced apoptosis 24 h and 96 h after exposure in RT2 cells
Because we observed that inhibition of MAPK signaling reduced proliferative capacity in RT2 cells, we next investigated whether inhibition of MAPK signaling also enhanced apoptosis in glioblastoma cells. In other cancer cell types, we have observed that inhibition of MAPK signaling enhances radiationinduced apoptosis within 24 h (Carter et al., 1998; Reardon et al., 1999; Park et al., 1999; Hagan et al., 2000) . In general agreement with our ®ndings in other cell types, neither radiation nor inhibition of the MAPK pathway caused a signi®cant increase in in Materials and methods. Cells were irradiated (2 Gy) and VEGF promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. VEGF-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 and the transfection eciency of the reporter plasmid between cells. (n=3+s.e.m.). Error bars are shown when greater than the datum symbol. (b) Twenty-four hours prior irradiation, T9 cells were transfected with a luciferase reporter construct coupled to the VEGF promoter. After 24 h, cells were treated with MEK1/2 inhibitor 30 min prior to irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and VEGF promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. VEGF-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 and the transfection eciency of the reporter plasmid between cells. (n=3+s.e.m.). (c) Twenty-four hours prior irradiation, RT2 cells were transfected with a luciferase reporter construct coupled to the VEGF promoter. After 24 h, cells were treated with MEK1/2 inhibitor 30 min prior to irradiation, as described in Materials and methods. Cells were irradiated (2 Gy) and VEGF promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. VEGF-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 and the transfection eciency of the reporter plasmid between cells. (n=3+s.e.m.). (d) Upper section, expression of VEGF protein in primary astrocytes, T9 and RT2 cells; Lower section, VEGF protein expression in RT2 cell lysates taken from the 180 min time point in c. Portions of lysates (*100 mg) from each plate were used to determine VEGF protein levels by immunoblotting as in Materials and methods. A representative experiment is shown (n=3). (e) Basal VEGF promoter function is partially dependent on MAPK activity in RT2 cells. Cells were transfected with the VEGF-luciferase reporter. After 24 h, cells were treated with MEK1/2 inhibitor for 2 h. VEGF-luciferase activity was determined as in Materials and methods apoptosis in RT2 cells. However inhibition of the MAPK pathway, combined with radiation exposure, enhanced RT2 cell apoptosis 24 h after exposure (Figure 8a ). Either serum starvation to reduce proliferation, removal of the MAPK inhibitor 6 h after radiation exposure, or incubation of cells with the pan caspase inhibitor z-VAD-FMK abolished the enhanced apoptotic response at 24 h. This data demonstrates the need for prolonged MAPK inhibition to achieve an enhanced apoptotic response at 24 h (Figure 8b ), in agreement Hagan et al., 2000) .
In a recent study, we demonstrated that to alter colony forming ability after radiation exposure, MAPK inhibition had to be prolonged for greater than 24 h (Hagan et al., 2000) . It was shown that prolonged MAPK inhibition enhanced radiation-induced apoptosis at 24 h, which was subsequently followed by a second wave of apoptosis 4 ± 6 days afterwards. In general agreement with these ®ndings, MAPK inhibition also caused a potentiation of radiation-induced apoptosis in RT2 cells 96 h after exposure (Figure 8c) . Removal of the MAPK inhibitor 24 h or 48 h after radiation exposure abolished the potentiation of apoptosis at 96 h (Figure 8c ). Collectively, these data demonstrate that MAPK inhibition potentiates radiation-induced killing in two waves. RT2 cells must have their MAPK activity inhibited for at least 48 h to become committed to the second wave of cell killing by this process.
Inhibition of the MAPK pathway reduces clonogenic survival of RT2 cells after multiple radiation exposures
To determine whether inhibition of MAPK signaling reduced the long-term proliferative potential of glioma cells after irradiation, RT2 cells were subjected to clonogenic survival assays. Initial single dose survival experiments demonstrated that removal of the MEK1/ 2 inhibitor 24 h after radiation exposure abolished any potentiating eects on reducing clonogenic survival (data not shown). Thus we adopted a fractionated radiation experimental approach. Exponentially growing cells were treated with either vehicle control P-incorporation into GST-c-Jun substrate, and are normalized to the speci®c activity in RT2 cells at time=0 from the means+s.e.m. of three independent experiments. Error bars are shown when greater than the datum symbol. (b) Twenty-four hours prior irradiation, RT2 cells were transfected with a luciferase reporter construct coupled to the VEGF promoter. In addition, cells were co-transfected with either a vector control plasmid, or plasmid to express dominant negative c-Jun (TAM67). After 24 h, cells were irradiated (2 Gy) and VEGF promoter activity determined over 0 ± 180 min as in Materials and methods. Cells were lysed and portions (*100 mg) from each plate used to determine luciferase activity as in Materials and methods. VEGF-luciferase activity data are shown as -fold increases activity and are normalized to activity at time=0 (n=3+s.e.m.) (DMSO) or with drug (PD98059, 10 mM) and were then either sham irradiated or irradiated with 362 Gy doses of ionizing radiation, one exposure per 24 h. Twenty-four hours after the ®nal exposure (96 h after the start of the experiment), viable cells were re-plated in the absence of drug for colony forming assays. Control and drug treated cells had similar colony forming abilities, with a trend for drug treated cells to have a slightly greater plating eciency. In contrast, irradiation of RT2 cells reduced survival to 60%. The addition of PD98059 increased the radiation sensitivity of RT2 cells, reducing survival to 40% (Figure 9 ). The sensitizing eect appeared to be weaker than previously observed in other mammary, squamous and prostate cancer cell lines Reardon et al., 1999; Hagan et al., 2000) .
Discussion
These studies were initiated to further understand the mechanism by which inhibition of the MAPK pathway sensitizes cancer cells to the cytotoxic eects of ionizing radiation. In addition, we examined potential interactions between radiation-induced MAPK signaling and downstream targets involved in tumor cell growth. Previous studies by this and several other groups have linked radiation-induced Raf-1/MAPK activity to protection from radiation-induced cell death following exposure.
Our studies demonstrated that radiation causes activation of the MAPK pathway in glioblastoma cells, in part via EGFR signaling. This is dierent to our ®ndings in mammary, squamous and prostate carcinoma cells where radiation-induced MAPK activity was obligatorily dependent on EGFR function. Activation of the MAPK pathway was dependent upon MEK1/2, as judged by the abilities of the chemically dissimilar MEK1/2 inhibitors PD98059, U0126 and SL327 to block activation, which was identical to our ®ndings in other systems. Blockade of MAPK activity for 24 h, but not 6 h, following radiation exposure enhanced apoptosis. Blockade of MAPK activity for 96 h, but not 24 h, following radiation exposure enhanced apoptosis at 96 h. When cells were exposed to multiple radiation exposures and incubated in the presence of MEK1/2 inhibitors for 96 h, a reduction in clonogenic survival was observed which was signi®-cantly greater than radiation exposure alone. Collectively, these data demonstrate that MAPK function protects glioblastoma cells from radiation-induced cell death.
MAPK signaling has been shown to play an important role in the control of both proliferation as well as growth factor-induced gene expression. Recently, we demonstrated that radiation-induced MAPK signaling could increase the activity of the promoters controlling expression of p21
, ERCC1 and XRCC1 . In RT2 cells, we found that radiation activated the VEGF promoter. Activation of the promoter was dependent on radiation-induced MAPK signaling. In addition, we discovered that radiation-induced VEGF promoter activation appears to be dependent on the coordinated eects of signaling by the MAPK and JNK pathways, and function of the AP-1 transcription factor complex. Since promoter activation does not always correlate with increased protein levels, we examined the eect of radiation both on the expression of VEGF and on VEGF protein levels in culture media. Radiation increased VEGF protein levels and increased VEGF levels in culture media, both of which were dependent on radiation-induced MAPK signaling. Collectively, our data argue that radiation-induced MAPK signaling may both promote growth directly via MAPK activation and indirectly in vivo by increasing expression of angiogenic factors such as VEGF.
Cancer is a progressive process involving systematic and temporal alterations in the expression of several genes, including positive acting oncogenes and negatively acting tumor suppressor genes (Fisher, 1984; Bishop, 1991; Vogelstein and Kinzler, 1991) . Recent studies have identi®ed another class of genes that contribute to the cancer paradigm, genetic elements that regulate expression of the oncogenic phenotype speci®cally in transformed and tumorigenic cells, i.e., progression modulating genes (Su et al., 1997 (Su et al., , 1999 (Su et al., , 2000 . Additionally, a relationship has been observed between PEG3 and elevated VEGF expression, an eect that is mediated at least in part by an enhancement of transcription from the VEGF gene (Su et al., 1999 (Su et al., , 2000 . In primary astrocytes, T9 and RT2 cells, our ®ndings were in general agreement with previously published data (Su et al., 1997 (Su et al., , 1999 (Su et al., , 2000 ; PEG3 expression was almost undetectable in primary astrocytes, but was expressed at high levels in T9 and RT2 cells. Of particular note, the relative protein levels of PEG3 in these dierent astrocytic cultures Figure 9 Inhibition of MAPK reduces survival of RT2 cells after multiple radiation exposures. Cells were pre-treated with either vehicle control (VEH, DMSO) or PD98059 (10 mM) for 30 min followed by irradiation (2 Gy) every 24 h for three consecutive days. Twenty-four hours after the ®nal exposure, cells were re-plated as single cells in the absence of inhibitors. The colony forming assay is described in Materials and methods. Data symbols represent the means of three separate experiments (+s.e.m.). *P50.01 less than control value; **P50.003 less than control value did not closely correlate with PEG3 promoter function. This suggests that in addition to any transcriptional control of the PEG3 promoter, a further posttranscriptional stabilization of PEG3 protein and potentially PEG-3 mRNA, may also play a role in the expression of PEG3 in speci®c tumor cells.
As noted above, increased expression of PEG-3 in ®broblast systems enhanced VEGF promoter function and tumorigenic behavior of cells overexpressing this protein in vivo. In agreement with these previous ®ndings, ectopic over expression of PEG-3 in primary astrocytes enhanced basal VEGF promoter activity eightfold. Surprisingly, over-expression of PEG-3 also increased basal MAPK activity 10-fold. When MAPK activity was blunted for 6 h in these cells, PEG-3-stimulated VEGF promoter activity was reduced by 60%. This data suggests that a portion of the mechanism by which enhanced PEG-3 expression can increase VEGF promoter function is via activation of the MAPK pathway. The mechanism by which overexpression of PEG-3 activates the MAPK pathway is at present not known. That inhibition of MAPK signaling did not completely abolish the PEG-3-dependent enhancement in VEGF promoter function also suggests that other additional mechanisms are recruited following PEG-3 over-expression to increase VEGF promoter activity.
In a parallel study, when PEG-3 expression was abolished in transformed RT2 cells, basal MAPK activity was reduced by 80% and basal VEGF promoter function reduced by *40%. Of note, inhibition of basal MAPK activity to a similar degree using a chemical inhibitor of MEK1/2 also reduced basal VEGF promoter function by *40%. This data further suggests that the relative expression level of PEG-3 can regulate VEGF promoter function in cells via MAPK-dependent and -independent mechanisms. Thus radiation may have the potential to activate the VEGF promoter via two inter-related mechanisms: a rapid direct signal transduction mechanism via MAPK and JNK signaling to the AP-1 transcription factor complex, and a second delayed mechanism that leads from MAPK signaling to enhanced PEG-3 protein levels. Enhanced PEG-3 expression can then subsequently promote additional VEGF synthesis via MAPK-dependent and independent mechanisms.
The mechanisms by which PEG-3 regulates the VEGF promoter are currently unclear. One mechanism appears to be enhanced MAPK activity. We found that neither primary astrocytes nor RT2 cells expressed signi®cant protein levels of the hypoxia-induced transcription factor HIF1a (data not shown). HIF1a has been shown in several studies to play an important role in regulating the VEGF promoter (Hossain et al., 2000; Mazure et al., 1997; Zundel et al., 2000) . In these studies, using both v-Ras transformed ®broblasts and glioma cells, hypoxia was proposed to increase expression of HIF1a via the PI 3 kinase pathway (Mazure et al., 1997; Zundel et al., 2000) . Other studies, under normal pO 2 conditions, have argued for cell type speci®c regulation of both HIF1a expression and VEGF promoter activity by either PI 3 kinase and/ or MAPK signaling (Mazure et al., 1997; Zundel et al., 2000; Pages et al., 2000; Rak et al., 2000) . A MAPKdependent trans-activating phosphorylation of HIF1a has also been proposed (Pages et al., 2000) . Further studies will be required to determine the precise MAPK-independent mechanisms by which PEG-3 protein regulates VEGF promoter function in RT2 cells.
Since RT2 cells did not express HIF1a, we performed studies to determine potential mechanisms for VEGF transcriptional control. Radiation activated not only the MAPK, but also the JNK, signaling pathway. The AP-1 transcription factor family complexes are a common point of signal transduction convergence for both MAPK and JNK signaling. Furthermore, it was recently suggested that PKCdependent activation of the VEGF promoter was AP-1 dependent (Hossain et al., 2000) . We found that inhibition of either MAPK signaling or of AP-1 function directly by use of dominant negative c-Jun (TAM67) inhibited VEGF promoter activation. Similar data were obtained using dominant negative JNK1 (not shown). TAM67 has been shown to inhibit classical' AP-1 complex function, as well as the function of the transcription factor Sp1 (e.g. Chen and Chang, 2000) . Multiple studies have suggested that Sp1, binding to a proximal region of the VEGF promoter, is vital in the regulation of promoter function by signaling pathways (e.g. Ryuto et al., 1996) . Collectively, these data demonstrate that coordinated signaling by MAPK and JNK has the potential to play a role in radiation-induced VEGF promoter activity.
RT2 cells were more tumorigenic in vivo than T9 cells (Barth, 1998) , and in agreement with VEGF expression promoting tumor growth, also expressed more VEGF under basal conditions. That radiation exposure enhanced expression of VEGF may have profound eects on tumor cell biology. It is known that glioblastoma tumors are both highly metastatic and contain a large vascular network, in agreement with our observation of high VEGF promoter activity and protein levels (Kraus et al., 2000; Huhn et al., 1999; Barth, 1998) . In addition, many of these tumors have been observed to proliferate, even during radiotherapy. One possible explanation for this phenomena may be that if radiation increases VEGF protein levels, then long-term tumor blood vessel growth and ultimately tumor growth can be enhanced by radiation exposure. We found that inhibiting MAPK in vitro caused a dose dependent reduction in VEGF promoter activity, suggesting that inhibition of MAPK signaling by itself may dramatically alter tumor growth potential in vivo through a reduction in VEGF output. In agreement with this hypothesis, inhibition of MAPK signaling alone in vivo permits prolonged survival of Fisher 344 rats injected intracranially with RT2 cells (data not shown). Further studies will be required to determine whether MAPK signaling plays a pivotal role in glioblastoma growth and angiogenesis in vivo.
Materials and methods

Materials
Primary astrocytes, T9 and RT2 cells are syngeneic with the Fisher 344 rat. T9 and RT2 cells were from the ATTCC (Bethesda, MD, USA). Fisher 344 rats were from Jackson Laboratories (Bar Harbor, ME, USA). Anti-p42 MAPK (sc-154), anti-phospho MAPK (sc-7383) and anti-VEGF (sc-507 and sc-1836) were from Santa Cruz Biotechnology (Santa Cruz Biotechnologies, CA, USA) (Carter et al., 1998; Dent et al., 1999) . The anti-PEG-3 antibody was generated as described (Su et al., 1999 (Su et al., , 2000 . Radiolabeled g-32 P-ATP was from NEN. The novel MEK1/2 inhibitors U0126 and SL327 were a kind gift from DuPont Pharmaceuticals Company (Wilmington, DE, USA) (Favata et al., 1998) . The MEK1/2 inhibitor PD98059 was a kind gift from Parke-Davis Pharmaceuticals Company (Ann Arbor, MI, USA). Western immunoblotting was performed using the Amersham Enhanced ChemiLuminescence (E.C.L.) system (Bucks, England, UK). Other reagents were as in (Carter et al., 1998; Dent et al., 1999; Reardon et al., 1999; Park et al., 1999) .
Methods
Generation of primary astrocytes Primary astrocytes were isolated and prepared from the brains of Fisher 344 rats as described in Ahmed et al. (2000) . Cells were cultured for 3 weeks prior to study.
Culture of primary astrocytes, T9 and RT2 cells Asynchronous cells were cultured in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 5% (v/v) fetal calf serum at 378C in 95% (v/v) air/5% (v/v) CO 2 . Cells were plated at a density 3.2610 4 cells/cm 2 plate area and grown for 4 days prior to further experimentation. For protein kinase and promoter function assays, cells were placed into 0.5% (v/v) serum containing media *18 h prior to irradiation. For studies examining apoptosis and proliferation, RT2 cells were not cultured in reduced serum media.
Exposure of cells to ionizing radiation and cell homogenization Cells were cultured in DMEM +5% (v/v) fetal calf serum as above. U0126/SL327/PD98059 treatment was from a 100 mM stock solution and the maximal concentration of vehicle (VEH, DMSO) in media was 0.02% (v/v). Cells were irradiated using a 60 Co source at dose rate of 2.1 Gy/min. Cells were maintained at 378C throughout the experiment except during the *1 min irradiation itself. Zero time is designated as the time point at which exposure to radiation ceased. After radiation-treatment cells were incubated for speci®ed times followed by aspiration of media and snap freezing at 7708C on dry ice. Cells were homogenized in 1 ml ice cold buer A (25 mM HEPES, pH 7.4 at 48C, 5 mM EDTA, 5 mM EGTA, 5 mM benzamidine, 1 mM phenylmethyl sulphonyl¯uoride, 1 mg/ml soybean trypsin inhibitor, 40 mg/ml pepstatin A, 1 mM Microcystin-LR, 0.5 mM sodium orthovanadate, 0.5 mM sodium pyrophosphate, 0.05 % (w/v) sodium deoxycholate, 1% (v/v) Triton X-100, 0.1% (v/v) 2-mercaptoethanol], with trituration using a P1000 pipette to lyse the cells. Homogenates were stored on ice prior to clari®cation by centrifugation (48C).
Immunoprecipitations from lysates Fifty microliters of Protein A agarose (Ag) slurry (25 ml bead volume) was washed twice with 1 ml PBS containing 0.1% (v/v) Tween 20, and resuspended in 0.1 ml of the same buer. Antibodies (2 mg, 20 ml), serum (20 ml) were added to each tube and incubated (3 h, 48C). For pre-conjugated antibodies, 10 ml of slurry (4 mg antibody) was used. Clari®ed equal aliquots of lysates (0.25 ml, *100 mg total protein) were mixed with Agconjugated antibodies in duplicate using gentle agitation (2.5 h, 48C). Ag-antibody-antigen complexes were recovered by centrifugation, the supernatant discarded, and washed (10 min) sequentially with 0.5 ml buer A (twice), PBS and buer B (25 mM HEPES, pH 7.4, 0.1 mM Na 3 VO 4 ). Protein concentration determinations were by the Method of Bradford.
Assay of p42
MAPK activity Immunoprecipitates were incubated (®nal volume 50 ml) with 50 ml of buer B containing 0.2 mM (g-32 P)ATP (5000 c.p.m./pmol), 1 mM Microcystin-LR, 0.5 mg/ml myelin basic protein (MBP), which initiated reactions at time=0. After 20 min, 40 ml of the reaction mixtures were spotted onto a 2 cm circle of P81 paper (Whatman, Maidstone, England, UK) and immediately placed into 180 mM phosphoric acid. Papers were washed four times (10 min each) with phosphoric acid, and once with acetone, and 32 P-incorporation into MBP was quanti®ed by liquid scintillation spectroscopy.
SDS poly-acrylamide gel electrophoresis (SDS ± PAGE) and Western blotting Cells were irradiated and at speci®ed time points/treatments media aspirated and the plates snap frozen. Cells were lysed with homogenization buer and subjected to immunoprecipitation. Immunoprecipitates were solubilized with 100 ml 56 SDS ± PAGE sample buer (192 mM glycine, 25 mM Tris/HCl, pH 8.3; 10% (w/v) SDS, 5 mM dithiothreitol, 0.5% (v/v) 2-mercaptoethanol), diluted to 250 ml with distilled water, and placed in a 1008C dry bath for 15 min. One hundred microliter aliquots of each time point were subjected to SDS ± PAGE on 10% (w/v) acrylamide gels. Note, the three main protein forms of VEGF (18.9, 16.5 and 12.1 kDa are not resolved from each other using PAGE containing this percentage of acrylamide). Gels were transferred to nitrocellulose by the Method of Towbin and Western blotting using speci®c antibodies performed as indicated. Blots were developed using Enhanced ChemiLuminescence (Amersham) using Fuji RX X-ray ®lm. Blots were digitally scanned using Adobe Photoshop 5.5, their color removed, and ®gures created in Microsoft PowerPoint.
Transfection of luciferase reporter constructs Cells were transfected using lipofectamine plus as per the manufacturer's instructions. Transfection eciency was determined by cotransfection of constitutive reporter constructs, either bgalactosidase or green¯uorescent protein, in parallel sets of plates.
Luciferase assays for promoter activity Luciferase assays were performed using rat PEG-3 and mouse VEGF promoters as described Park et al. (1999) . Assays were performed using a kit (Promega) as per the manufacturer's instructions. Luciferase activity was measured in a Bertold LB9501 # luminometer for 20 s per assay. Data were corrected for total cell protein in each cell type, using the Method of Bradford, and by transfection eciency determined from parallel reporter construct data.
Terminal uridyl-nucleotide end labeling (TUNEL) for apoptosis Cells were grown in 100 mm dishes as described, treated with or without varying concentrations of U0126/ SL327/PD98059/DMSO control 30 min prior to irradiation and irradiated (2 Gy). Cells were isolated 24 h after irradiation by trypsinization followed by centrifugation onto glass slides (cytospin). Terminal uridyl-nucleotide end labeling (TUNEL) was performed on these cells as described previously (Carter et al., 1998; Park et al., 1999) . Randomly selected ®elds of ®xed cells (*150 cells per ®eld, n=5 per slide) were counted initially using propidium iodide counter stain, followed by examination and counting of TUNEL positive staining cells of the same ®eld under FITC/ uorescence light.
Cell cycle analysis: propidium iodide staining of cells Cells were isolated by tryptic digestion at the indicated times after various treatments and aliquots containing 1610 6 cells were pelleted by centrifugation at 1500 r.p.m., 48C for 5 min and resuspended in 1.5 ml of PBS followed by the addition of 3 ml of 100% (v/v) ETOH (67% (v/v) ETOH Final) and incubated on ice at 48C for 3 h. Cells were pelleted by centrifugation as above, supernatant removed and resuspended in 1.0 ml of propidium iodide stain containing 3.8 mM sodium citrate, 0.5 mg/ml RNAse A and 0.01 mg/ ml propidium iodide and incubated on ice at 48C overnight. Cells were pelleted by centrifugation as above, supernatant removed and resuspended in 1.0 ml of PBS. Cells were analysed with a Becton-Dickinson FACScan¯ow cytometer and Verity Winlist software .
Colony forming (clonogenic) assay Cells were pre-treated with MEK1/2 inhibitor as indicated, 2 h prior to exposure. Cells were irradiated (2 Gy) on three consecutive days. After a further 24 h (4 days in inhibitor total time), cells were isolated by tryptic digestion and single cell suspensions plated on Linbro 1 plates at densities of 500 cells/well and 1000 cells/ well. Colony formation was de®ned as a colony of 50 cells or greater, 10 days after plating.
Data analysis
Comparison of the eects of treatments was done using one way analysis of variance and a two tailed Student's t-test. Dierences with a P-value of 50.05 were considered statistically signi®cant. Experiments shown, except where indicated, are the means of multiple points from multiple separate experiments (+s.e.m.).
Abbreviations MAPK, mitogen activated protein kinase; JNK, c-Jun NH 2 -terminal kinase; VEGF, vascular endothelial growth factor; PEG-3, progression elevated gene-3.
